Alexion – Health

FDA gifts Alexion quick OK for Soliris follow-up Ultomiris

Alexion was expecting a decision on its Soliris successor by February, but thanks to a quick review from U.S. regulators, it’s made its way onto 2018’s list of new drug approvals. The agency green-lighted the drug, Ultomiris, last week as a treatment for rare and life-threatening blood disease paroxysmal nocturnal hemoglobinuria. The new and improved… Read More »

U.S. FDA approves Alexion Pharma's blood disorder drug

(Reuters) – The U.S. Food and Drug Administration has approved Alexion Pharmaceuticals Inc’s blood disorder drug Ultomiris, the pharma regulator’s website showed on Friday. The drug aims to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare, acquired, life-threatening disorder in which red blood cells divide prematurely. Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila… Read More »